^
MGMT underexpression
Pituitary Gland Carcinoma
temozolomide
Sensitive: C3 – Early Trials
SDHB mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive: C4 – Case Studies
MSH2 mutation + MSH6 mutation
Pituitary Gland Carcinoma
pembrolizumab
Sensitive: C4 – Case Studies
TMB-L + PD-L1 underexpression
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant: C4 – Case Studies
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive: C4 – Case Studies
ATRX mutation + TP53 mutation + PTEN mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive: C4 – Case Studies
TMB-H
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Resistant: C4 – Case Studies
TMB-H
Pituitary Gland Carcinoma
temozolomide
Resistant: C4 – Case Studies
MSH2 deletion + MSH6 deletion
Pituitary Gland Carcinoma
temozolomide
Resistant: C4 – Case Studies